{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:58:46Z","timestamp":1789142326349,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40122-022-00388-8","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T13:03:48Z","timestamp":1651583028000},"page":"701-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02439320","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02605174","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03670810","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03962738","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-0951","authenticated-orcid":false,"given":"John H.","family":"Krege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin K.","family":"Baygani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"388_CR1","doi-asserted-by":"crossref","unstructured":"IHS. ICHD-II Classification: parts 1\u20133: primary, secondary and other. Cephalalgia. 2004;24(1_suppl):23\u2013136.","DOI":"10.1111\/j.1468-2982.2004.00653.x"},{"issue":"1","key":"388_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.","journal-title":"J Headache Pain"},{"issue":"10100","key":"388_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211\u201359.","journal-title":"The Lancet"},{"issue":"1","key":"388_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3\u201320.","journal-title":"Headache"},{"key":"388_CR5","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD, et al. Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health. 2020;11:2150132720963680.","journal-title":"J Prim Care Community Health"},{"key":"388_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1749-6632.1990.tb16912.x","volume":"600","author":"PP Humphrey","year":"1990","unstructured":"Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci. 1990;600:587\u201398.","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"388_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000119098","volume":"36","author":"GR Martin","year":"1996","unstructured":"Martin GR. Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action. Eur Neurol. 1996;36(Suppl 2):13\u20138.","journal-title":"Eur Neurol"},{"issue":"2","key":"388_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005344-199808000-00008","volume":"32","author":"AA Parsons","year":"1998","unstructured":"Parsons AA, Raval P, Smith S, Tilford N, King FD, Kaumann AJ, et al. Effects of the novel high-affinity 5-HT(1B\/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998;32(2):220\u20134.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 19","key":"388_CR9","first-page":"388","volume":"17","author":"J Longmore","year":"1997","unstructured":"Longmore J, Razzaque Z, Hargreaves R, Schofield W, Pickard J, Boulanger C. Rizatriptan selectively contracts human middle meningeal over coronary artery: comparison with sumatriptan. Cephalagia. 1997;17(suppl 19):388\u20139.","journal-title":"Cephalagia"},{"key":"388_CR10","first-page":"386","volume":"16","author":"P Gupta","year":"1996","unstructured":"Gupta P, Scatchard J, Shepperson N, Wallis R, Wythes M. In vitro pharmacology of eletriptan (UK-116044), a potent partial agonist at the \u201c5HT 1D-like\u201d receptor in the dog saphenous vein. Cephalalgia. 1996;16:386.","journal-title":"Cephalalgia"},{"issue":"2","key":"388_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/01.CIR.87.2.401","volume":"87","author":"PD MacIntyre","year":"1993","unstructured":"MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87(2):401\u20135.","journal-title":"Circulation"},{"issue":"5","key":"388_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325.","journal-title":"Headache"},{"key":"388_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/JPR.S132833","volume":"11","author":"A Negro","year":"2018","unstructured":"Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515\u201326.","journal-title":"J Pain Res"},{"issue":"1","key":"388_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/head.12962","volume":"57","author":"DC Buse","year":"2017","unstructured":"Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(1):31\u201344.","journal-title":"Headache"},{"issue":"10","key":"388_CR15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/head.13179","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(10):1507\u201321.","journal-title":"Headache"},{"issue":"10","key":"388_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159\u201369.","journal-title":"Cephalalgia"},{"key":"388_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltran","year":"2018","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88\u201397.","journal-title":"Pharmacol Ther"},{"key":"388_CR18","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine. Neurology. 2018;91:e2222\u201332.","journal-title":"Neurology"},{"issue":"7","key":"388_CR19","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u2013904.","journal-title":"Brain"},{"issue":"11","key":"388_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343\u201357.","journal-title":"Cephalalgia"},{"key":"388_CR21","doi-asserted-by":"crossref","first-page":"251581632095817","DOI":"10.1177\/2515816320958176","volume":"3","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study. Cephalalgia Rep. 2020;3:2515816320958176.","journal-title":"Cephalalgia Rep"},{"issue":"3","key":"388_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294\u2013304.","journal-title":"Cephalalgia"},{"issue":"1","key":"388_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action\u2014review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.","journal-title":"J Headache Pain"},{"issue":"24","key":"388_CR24","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Haanes KA, van den Bogaerdt A, Bogers AJJC, Zanelli E, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019;176(24):4681\u201395.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"388_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90.","journal-title":"J Headache Pain"},{"issue":"5","key":"388_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755\u201365.","journal-title":"Headache"},{"key":"388_CR27","doi-asserted-by":"crossref","unstructured":"(IHS) HCCotIHS. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"2","key":"388_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1526-4610.2011.02052.x","volume":"52","author":"TW Ho","year":"2012","unstructured":"Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52(2):224\u201335.","journal-title":"Headache"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-022-00388-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T16:36:42Z","timestamp":1652373402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-022-00388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40122-022-00388-8","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}